FDA OKs J&J’s Stelara for ulcerative colitis

The FDA approves Johnson & Johnson (NYSE:JNJ) unit Janssen Pharmaceutical’s Stelara (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis, its fifth indication in the U.S.

The FDA first approved the IL-12/IL-23 antagonist in September 2009 for psoriasis.

Shares up 1% premarket on light volume.

https://seekingalpha.com/news/3507198-fda-oks-j-and-js-stelara-ulcerative-colitis